You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics

From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

n = 95 Median
Age 77 (48-91) years
Sex  
Male 49 (51.6%)
Female 46 (48.4%)
Operable 14 (14.7%)
Inoperable 81 (85.3%)
KPS  
80-100 63 (66.3%)
<70 32 (32.7%)
Clinical follow-up 16.33 (1.13-64.2) months